

Date: 13.12.2017

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001


**Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 33 of SEBI (LODR) Regulations, 2015.**

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the Second Quarter/Half Year Ended 30<sup>th</sup> September, 2017.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Second Quarter/ Half Year Ended 30<sup>th</sup> September, 2017 by the Auditors.

This is for your Information and Necessary Records.

Thanking you  
For **TRIMURTHI LIMITED**

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 13.12.2017

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 13/12/2017 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Wednesday, the 13<sup>th</sup> day of December, 2017 at Registered Office, have approved and taken on record the following:


1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the Quarter II and Half Year ended 30<sup>th</sup> September, 2017 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
3. The Board has considered and approved to transfer all the shares, wherein the dividend is outstanding for more than seven consecutive years to IEPF Fund/IEPF Suspend Account.


There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 04.30 P.M. and Concluded at 06:00 PM

Request you to take same on records.

Thanking you  
for **TRIMURTHI LIMITED**

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
SCHEDULE III OF THE COMPANIES ACT 2013  
STANDALONE UNAUDITED STATEMENT OF PROFIT AND LOSS FOR THE QUARTER ENDED SEPTEMBER, 2017.

**TRIMURTHI**  
GROUP

**PART-I**

Particulars	Quarter Ended			Half Yearly Ended	
	30-09-2017	30/06/2017	30-09-2016	30-09-2017	30-09-2016
	Unaudited	UnAudited	Unaudited	Unaudited	Unaudited
<b>I. Income From Operations</b>					
Net Sales / Income from Operations	27.25	50.88	53.85	78.13	197.00
Other Income	0.05	2.11	-Nil-	2.16	26.99
<b>II. Total Income</b>	<b>27.30</b>	<b>52.99</b>	<b>53.85</b>	<b>80.29</b>	<b>224.00</b>
<b>III. Expenses</b>					
a. Cost of Material Consumed	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Purchase of Stock-in-trade	2.79	0.29	63.38	3.08	236.79
c. Changes in inventories of finished goods, Work in progress and Stock in trade	(0.53)	21.92	(24.81)	21.39	(36.97)
d. Employee benefits expense	5.47	5.81	5.43	11.28	10.71
e. Rent	0.55	0.75	0.75	1.30	1.50
f. Finance Cost	0.00	0.00	-Nil-	0.00	0.00
g. Depreciation	4.01	3.69	2.35	7.70	5.25
h. Other Expenditure	2.74	5.36	5.52	8.10	12.99
<b>Total</b>	<b>15.03</b>	<b>37.82</b>	<b>52.63</b>	<b>52.85</b>	<b>230.26</b>
<b>IV. Profit/ (Loss) before Exceptional and Tax (II-III)</b>	<b>12.27</b>	<b>15.17</b>	<b>1.22</b>	<b>27.44</b>	<b>(6.27)</b>
<b>V. Exceptional Items</b>	Nil	Nil	Nil	Nil	Nil
<b>VI. Profit/ (Loss) before tax (IV-V)</b>	<b>12.27</b>	<b>15.17</b>	<b>1.22</b>	<b>27.44</b>	<b>(6.27)</b>
<b>VII. Tax expense:</b>	2.60	4.37	(0.03)	6.97	0.11
(1) Current tax	2.63	4.66	Nil	7.29	Nil
(2) Deferred tax	(0.03)	(0.29)	(0.03)	(0.32)	0.11
<b>VIII. Net Profit/ (Loss) for the period from continuing operations (VI-VII)</b>	<b>9.67</b>	<b>10.80</b>	<b>1.25</b>	<b>20.47</b>	<b>(6.38)</b>
<b>IX. Profit/(loss) from discontinued operations</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>X. Tax expenses of discontinued operations</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XI. Profit/(loss) from Discontinued operations (after tax) (IX-X)</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XII. Profit/(loss) for the period (VIII+XI)</b>	<b>9.67</b>	<b>10.80</b>	<b>1.25</b>	<b>20.47</b>	<b>(6.38)</b>
<b>XIII. Other Comprehensive Income</b>					
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XIV. Total Comprehensive Income for the period (XII+XIII) (Comprising Profit (Loss) and Other comprehensive Income for the period )</b>	<b>9.67</b>	<b>10.80</b>	<b>1.25</b>	<b>20.47</b>	<b>(6.38)</b>
<b>XV. Earnings per equity share (for continuing operation):</b>					
(1) Basic	0.12	0.13	0.02	0.25	(0.08)
(2) Diluted	0.12	0.13	0.02	0.25	(0.08)
<b>XVI. Earnings per equity share (for discontinuing operation):</b>					
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XVII. Earnings per equity share (for discontinuing &amp; continuing operation):</b>					
(1) Basic	0.12	0.13	0.02	0.25	(0.08)
(2) Diluted	0.12	0.13	0.02	0.25	(0.08)



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

**TRIMURTHI**  
GROUP

**Segment Reporting**

Particulars	Quarters ended			Half Yearly Ended	
	30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
<b>1. Segment Revenue</b>					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	21.64	21.38	14.02	43.02	24.21
c. Investments	0.00	0.00	0.08	0.00	2.23
d. Trading in Shares	5.51	31.62	39.76	37.13	197.56
<b>Total</b>	<b>27.16</b>	<b>52.99</b>	<b>53.86</b>	<b>80.15</b>	<b>224.00</b>
<b>Less: Inter Segment Revenue</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>27.16</b>	<b>52.99</b>	<b>53.86</b>	<b>80.15</b>	<b>224.00</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	14.62	15.63	6.93	30.25	8.99
c. Investments	0.00	0.00	2.36	0.00	2.23
d. Trading in Shares	(2.49)	(0.45)	(5.79)	(2.94)	(17.48)
<b>Total</b>	<b>12.13</b>	<b>15.18</b>	<b>3.50</b>	<b>27.31</b>	<b>(6.27)</b>
<b>Less:</b>					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>12.13</b>	<b>15.18</b>	<b>3.50</b>	<b>27.31</b>	<b>(6.27)</b>
<b>3. Capital Employed</b>					
a. Pharma Business	0.00	0.00	2.24	0.00	2.24
b. Financial Services	(33.82)	678.97	471.51	645.15	471.51
c. Investments	0.00	184.34	359.69	184.34	359.69
d. Trading in Shares	46.24	305.74	304.28	351.98	304.28
<b>Total</b>	<b>12.42</b>	<b>1169.06</b>	<b>1137.71</b>	<b>1181.47</b>	<b>1137.71</b>

**Notes:**

- The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.1(iii) has been availed. Hence, figures of corresponding previous quarter and previous year have not been provided.
- There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retrospective application of certain Ind AS as permitted under Ind AS 101.
- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Wednesday, 13th December, 2017.
- The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 30th September, 2017. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The results are also available on the website of the Company
- These results do not include IND AS compliant result for the immediate preceding quarter (30-06-2017) (Unaudited), Corresponding Quarter for Previous Year (30-09-2016) (Unaudited) as the same is not mandatory as per the SEBI's Circular dated 5th July 2016.

Place : Hyderabad  
Date : 13-12-2017



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE ASSETS AND LIABILITIES FOR THE YEAR ENDED ON 31-03-2017

Statement of Assets and Liabilities

		(INR, in Lakhs)
Particulars		Half Year Ended 30-09-2017 Unaudited
<b>ASSETS</b>		
<b>1 Non Current Assets</b>		
a	Property, Plant and Equipments	68.32
b	Capital Work In Progress	-Nil-
c	Investment Property	-Nil-
d	Goodwill	-Nil-
e	Other Intangible Assets	2.40
f	Intangible Assets under development	-Nil-
g	Biological assets other than bearer plants	-Nil-
h	Financial Assets:	
	Investments	184.34
	Trade Receivables	-Nil-
	Loans	20.90
	Others	-Nil-
i	Deferred Tax Assets (net)	-Nil-
j	Other Non Current Assets	-Nil-
	<b>Total Non Current Assets</b>	<b>275.97</b>
<b>2 Current Assets</b>		
a	Inventories	0.53
b	Financial Assets:	
	Investments	-Nil-
	Trade Receivables	67.62
	Cash and Cash Equivalents	10.53
	Bank balances other than above	-Nil-
	Loans	831.45
	Others	-Nil-
c	Current Tax Assets (net)	-Nil-
d	Other Current Assets	9.88
	<b>Total Current Assets</b>	<b>920.00</b>
	<b>Total Assets</b>	<b>1,195.96</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
a	Equity Share Capital	810.00
b	Other Equity	369.61
	<b>Total - Equity</b>	<b>1,179.61</b>
<b>2 Liabilities</b>		
<b>Non Current Liabilities</b>		
a	Financial Liabilities	
	Borrowings	-Nil-
	Trade Payables	-Nil-
	Other Financial Liabilities	-Nil-
b	Provisions	-Nil-
c	Deferred Tax Liabilities (net)	1.96
d	Other Non Current Liabilities	-Nil-
	<b>Total Non Current Liabilities</b>	<b>1.96</b>
<b>Current Liabilities</b>		
a	Financial Liabilities	
	Borrowings	
	Trade Payables	1.39
	Other Financial Liabilities	-Nil-
b	Other Current Liabilities	5.67
c	Provisions	-Nil-
d	Current Tax Liabilities (net)	7.33
	<b>Total Current Liabilities</b>	<b>14.39</b>
	<b>Total - Equity and Liabilities</b>	<b>1,195.96</b>

Place: Hyderabad  
Date: 13-12-17

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com  
info@pmurali.com

Website : www.pmurali.com

To

The Board of Directors

Trimurthi Limited

Hyderabad

Limited Review Report for the quarter and half year ended 30<sup>th</sup> September, 2017

1. We have reviewed the accompanying statement of unaudited financial results of **M/s. Trimurthi Limited** (The statement) for the quarter and half year ended 30<sup>th</sup> September, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 13<sup>th</sup> December, 2017. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S

A Krishna Rao

Partner

M.No. 020085



Place: Hyderabad

Date: 13<sup>th</sup> December 2017